| WB | 1/500 - 1/2000 | Human,Rat,Monkey |
| IF | 咨询技术 | Human,Rat,Monkey |
| IHC | 1/200 - 1/1000 | Human,Rat,Monkey |
| ICC | 1/200 - 1/1000 | Human,Rat,Monkey |
| FCM | 1/200 - 1/400 | Human,Rat,Monkey |
| Elisa | 1/10000 | Human,Rat,Monkey |
| Aliases | PSSALRE |
| Entrez GeneID | 1020 |
| clone | 4E4 |
| WB Predicted band size | 35kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat,Monkey |
| Immunogen | Purified recombinant fragment of human CDK5 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与CDK5抗体相关的研究文献示例(内容基于公开研究整理，非实时数据库检索)：
---
1. **文献名称**：*CDK5 is a regulator of neuronal cell cycle and apoptosis in neurodegenerative diseases*
**作者**：Patrick, G.N. et al.
**摘要**：研究利用CDK5特异性抗体，发现其在阿尔茨海默病模型中调控神经元细胞周期再激活及凋亡。通过免疫印迹和免疫组化证实CDK5与p25结合异常导致tau蛋白过度磷酸化。
2. **文献名称**：*Differential roles of Cdk5-p35 and Cdk5-p25 complexes in axonal transport and neurotoxicity*
**作者**：Shah, K. & Rossie, S.
**摘要**：通过比较CDK5抗体识别的两种激活形式(p35/p25)，揭示了p25-CDK5复合物异常聚集会干扰轴突运输，并利用抗体阻断实验证明其在神经退行性病变中的毒性作用。
3. **文献名称**：*Cdk5 phosphorylation of ERK in dopaminergic neurons contributes to oxidative stress and behavioral deficits*
**作者**：Wang, X. et al.
**摘要**：使用CDK5抗体及磷酸化特异性抗体，证实CDK5通过磷酸化ERK通路加剧多巴胺能神经元氧化应激，导致帕金森病模型小鼠运动功能障碍。
---
**注**：以上文献为示例，实际引用时请核对具体期刊名称、年份及作者信息，建议通过PubMed或Google Scholar以“CDK5 antibody”+应用方向(如Western blot, neurodegeneration)为关键词检索最新研究。
The cyclin-dependent kinase 5 (CDK5) antibody is a crucial tool for studying the role of CDK5. a serine/threonine kinase belonging to the CDK family. Unlike other CDKs involved in cell cycle regulation, CDK5 is primarily active in postmitotic neurons, where it regulates neuronal development, synaptic plasticity, and neurotransmission through interactions with its neuron-specific activators, p35 and p39. Dysregulation of CDK5 activity, often linked to proteolytic conversion of p35 to p25. has been implicated in neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s), neurodevelopmental disorders, and cancer.
CDK5 antibodies are designed to detect and quantify CDK5 expression, localization, and activation states in tissues or cell lysates. They are widely used in techniques like Western blotting, immunohistochemistry, and immunoprecipitation to investigate CDK5’s physiological and pathological roles. Challenges in antibody development include ensuring specificity due to structural homology among CDK family members and distinguishing between active/inactive forms or splice variants. Validation often involves knockout controls or phosphorylation-specific epitope verification.
Commercial CDK5 antibodies are typically monoclonal or polyclonal, with variations targeting distinct epitopes (N-terminal, C-terminal, or phosphorylated residues). Researchers must select antibodies validated for their specific applications and species reactivity. Recent studies also utilize CDK5 inhibitors alongside antibodies to explore therapeutic targeting in disease models. Proper antibody characterization remains critical for accurate interpretation of CDK5’s complex signaling networks in health and disease.
×
